ArticleThorax2024
Short peripheral blood leukocyte telomere length in rheumatoid arthritis-interstitial lung disease.
Open access · bronzeAbstract read
In one paragraph
Article in Thorax, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Lung disease in rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Telomere-associated non-malignant pulmonary diseases: Pathogenic mechanisms and therapeutic strategies.Acta pharmaceutica Sinica. B · 2026Review
- Radiological diversity in rheumatoid arthritis associated with usual interstitial pneumonia (RA-UIP) and its therapeutic implications: towards a generalizable framework of interstitial lung disease treatment.Respiratory research · 2026Review
- Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions.BMC medicine · 2026Review
- Advances in the Diagnosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Integrating Conventional Tools and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Lengthened telomere length in peripheral blood leukocytes in patients with rheumatoid arthritis complicated with airway disease.BMC rheumatology · 2025Article
- Precision medicine in rheumatoid arthritis-associated interstitial lung disease: current evidence and future directions.Current opinion in pulmonary medicine · 2025Review
- Peripheral and pulmonary telomere lengths in patients with non-idiopathic pulmonary fibrosis interstitial lung diseases.BMC pulmonary medicine · 2025Article
- Treating connective tissue disease-associated interstitial lung disease - think outside the box: a perspective.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-Associated Interstitial Lung Disease Subtypes.Arthritis care & research · 2025Article
- Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.Drugs & aging · 2025Review
- Navigating interstitial lung disease associated with rheumatoid arthritis (RA-ILD): from genetics to clinical landscape.Frontiers in medicine · 2025Review
- Exploring Antifibrotic Strategies for Interstitial Lung Disease in Rheumatoid Arthritis: A Narrative Review.Open access rheumatology : research and reviews · 2025Review
- New insights into the role of cellular senescence and rheumatic diseases.Frontiers in immunology · 2025Review
- Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy.Current rheumatology reports · 2024Review
- Leukocytes telomere length as a biomarker of adverse drug reactions induced by Osimertinib in advanced non-small cell lung cancer.Scientific reports · 2024Article
- Article
- Identification and Validation of Telomere-Related Gene Signature in Intervertebral Disc Degeneration.Cureus · 2024Article
- Casual effects of telomere length on sarcoidosis: a bidirectional Mendelian randomization analysis.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 2 countries.
Tracy J Doyle *Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA tjdoyle@bwh.harvard.edu.ORCID 0000-0002-0770-1059
Pierre-Antoine Juge *Université Paris Cité, INSERM UMR 1152, F-75018, Paris, France.
Anna L PeljtoDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, California, USA.
Seoyeon LeeDepartment of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, California, USA.
Avram D WaltsDepartment of Medicine, National Jewish Health, Denver, Colorado, USA.
Anthony Joseph EspositoDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-8636-0845
Sergio PoliDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Ritu GillDepartment of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Hiroto HatabuDepartment of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Mizuki NishinoDepartment of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Paul F DellaripaDepartment of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Michael E WeinblattDepartment of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Nancy A ShadickDepartment of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
M Kristen DemoruelleDepartment of Medicine, Division of Rheumatology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Jeffrey A SparksDepartment of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-5556-4618
Ivan O RosasDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA.
Benjamin GrangerSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), Hôpital Pitié Salpétrière, Public Health Department, F75013, Paris, France.
Kevin D DeaneDepartment of Medicine, Division of Rheumatology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Bruno CrestaniUniversité Paris Cité, INSERM UMR 1152, F-75018, Paris, France.
Paul J WoltersDepartment of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Denver, Colorado, USA.
Philippe Dieudé *Université Paris Cité, INSERM UMR 1152, F-75018, Paris, France.
Joyce S Lee *Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Denver, Colorado, USA.
Brigham and Women's Hospital · USUniversity of Colorado Denver · USUniversité Claude Bernard Lyon 1 · FRUniversity of California, San Francisco · USBaylor College of Medicine · USBeth Israel Deaconess Medical Center · USInserm · FRNational Jewish Health · USNorthwestern University · US
Funding
The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2MClinical Genetics and Screening for Pulmonary FibrosisR01HL130974 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GARY MATTHEW HUNNINGHAKE, Benjamin Alexander Raby · 2016 to 2026
$10.0MVERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8MJoint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4MGenetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung AbnormalitiesR01HL135142 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO, GARY MATTHEW HUNNINGHAKE · 2017 to 2026
$7.7MInterstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4MLung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II CellsR01HL139897 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Paul j WOLTERS · 2018 to 2026
$5.5MCore 2 - Mucosal Immunobiology Core (MIC)P30AR079369 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Vernon Michael Holers · 2021 to 2026
$4.7MRheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7MRheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular PhenotypesR01HL155522 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks, George R Washko · 2022 to 2026
$3.5MAutomated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentR01CA203636 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NISHINO, MIZUKI · 2017 to 2021
$2.9MClinical and Molecular Characteristics of Rheumatoid Arthritis-associated ILDK23HL119558 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DOYLE, TRACY JENNIFER · 2015 to 2018
$763kNCI NIH HHS R01 CA203636NCI NIH HHS U01 CA209414NHLBI NIH HHS F32 HL151132NHLBI NIH HHS K23 HL119558NHLBI NIH HHS K23 HL138131NHLBI NIH HHS L30 HL149048NHLBI NIH HHS R01 HL111024NHLBI NIH HHS R01 HL130974NHLBI NIH HHS R01 HL135142NHLBI NIH HHS R01 HL139897NHLBI NIH HHS R01 HL155522NHLBI NIH HHS R03 HL148484NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS P30 AR079369NIAMS NIH HHS R01 AR077607
Abstract
Shortened telomere lengths (TLs) can be caused by single nucleotide polymorphisms and loss-of-function mutations in telomere-related genes (TRG), as well as ageing and lifestyle factors such as smoking. Our objective was to determine if shortened TL is associated with interstitial lung disease (ILD) in individuals with rheumatoid arthritis (RA). This is the largest study to demonstrate and replicate that shortened peripheral blood leukocytes-TL is associated with ILD in patients with RA compared with RA without ILD in a multinational cohort, and short PBL-TL was associated with baseline disease severity in RA-ILD as measured by forced vital capacity percent predicted.
Indexed as
Arthritis, RheumatoidLung Diseases, InterstitialHumansSmokingTelomereTelomere Shorteninginterstitial fibrosisrheumatoid lung disease
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.